Development of a Novel Cone-Rod Dystrophy 6 (CORD6) Mouse Model to Assess AAV-CRISPR/Cas9-Based Therapies

被引：0
|
作者：
Mellen, Russell W. [1 ]
Boye, Sanford L. [2 ]
McCullough, K. Tyler [1 ]
Fajardo, Diego [1 ]
Crosson, Sean [1 ]
Calabro, Kaitlyn [1 ]
Dizhoor, Alex M. [3 ]
Boye, Shannon E. [1 ]
机构：
[1] Univ Florida, Dept Ophthalmol, Gainesville, FL USA
[2] Univ Florida, Dept Pediat, Powell Gene Therapy Ctr, Gainesville, FL USA
[3] Salus Univ, Penn Coll Optometry, Elkins Pk, PA USA
来源：
MOLECULAR THERAPY | 2020年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
604
引用
收藏
页码：267 / 267
页数：1
相关论文
共 19 条
  • [1] AAV-CRISPR/Cas9 Gene Editing is Therapeutic in a Novel, Humanized Mouse Model of GUCY2D-Associated Cone Rod Dystrophy (CORD6)
    Mellen, Russell W.
    McCullough, K. Tyler
    Fajardo, Diego
    Calabro, Kaitlyn
    Crosson, Sean
    Xu, Emily
    Boye, Sanford L.
    Boye, Shannon E.
    MOLECULAR THERAPY, 2022, 30 (04) : 566 - 566
  • [2] Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6
    Mellen, Russell W.
    Calabro, Kaitlyn R.
    Mccullough, K. Tyler
    Crosson, Sean M.
    de la Cova, Alejandro
    Fajardo, Diego
    Xu, Emily
    Boye, Sanford L.
    Boye, Shannon E.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 48 - 64
  • [3] An AAV-CRISPR/Cas9 Gene Editing Approach for GUCY2D-Associated Cone Rod Dystrophy (CORD6)
    Mellen, R. W.
    McCullough, K. T.
    Boye, S. L.
    Fajardo, D.
    Strang, C. E.
    Witherspoon, C. D.
    Hill, J. L.
    Gloskowski, S. W.
    Dass, A.
    Gamlin, P. D.
    Maeder, M. L.
    Boye, S. E.
    MOLECULAR THERAPY, 2019, 27 (04) : 429 - 429
  • [4] An AAV-CRISPR/Cas9 gene editing approach for GUCY2D-associated cone rod dystrophy (CORD6)
    Mccullough, Kevin
    Boye, Sanford L.
    Fajardo, Diego
    Strang, Christianne E.
    Witherspoon, Douglas C.
    Gloskowski, Sebastian
    Dass, Abhishek
    Gamlin, Paul D.
    Maeder, Morgan
    Boye, Shannon Elizabeth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [5] Localisation of a gene for dominant cone-rod dystrophy (CORD6) to chromosome 17p
    Kelsell, RE
    Evens, K
    Gregory, CY
    Moore, AT
    Bird, AC
    Hunt, DM
    HUMAN MOLECULAR GENETICS, 1997, 6 (04) : 597 - 600
  • [6] Biochemical consequences of ROS-GC1 gene mutation linked with cone-rod dystrophy (CORD6)
    Duda, T
    Krishnan, A
    Sharma, RK
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S216 - S216
  • [7] Deregulation of calcium feedback via calcium sensor proteins, GCAPs, triggers photoreceptor death in dominant cone-rod dystrophy CORD6 mouse model.
    Olshevskaya, Elena V.
    Sato, Shinya
    Peshenko, Igor V.
    Dizhoor, Alexander M.
    Kefalov, Vladimir J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [8] Assessment of Efficacy 6 Months After Systemic Injection of an AAV-CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
    Young, Courtney
    Gibbs, Elizabeth
    Perez, Jesus
    Emami, Michael
    Bengtsson, Niclas
    Chamberlain, Jeffrey
    Pyle, April
    Spencer, Melissa
    MOLECULAR THERAPY, 2022, 30 (04) : 491 - 491
  • [9] Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase
    Gregory-Evans, K
    Kelsell, RE
    Gregory-Evans, CY
    Downes, SM
    Fitzke, FW
    Holder, GE
    Simunovic, M
    Mollon, JD
    Taylor, R
    Hunt, DM
    Bird, AC
    Moore, AT
    OPHTHALMOLOGY, 2000, 107 (01) : 55 - 61
  • [10] Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
    Oliver, Adrian
    Nelson, Christopher
    Bohning, Joel
    Gilcrest, Kylie
    Gersbach, Charles
    MOLECULAR THERAPY, 2020, 28 (04) : 6 - 6
12